Company profile: OctreoPharm Sciences
1.1 - Company Overview
Company description
- Provider of radiopharmaceuticals and theranostic solutions for neuroendocrine tumors, including OPS201, a peptide for PRRT with 90Yttrium or 177Lutetium, and OPS202, a 68Gallium-labeled PET imaging agent targeting somatostatin receptors.
Products and services
- Theranostics: Integrated approach combining diagnostics and therapeutics with radiopharmaceuticals to deliver personalized treatment pathways for neuroendocrine tumors
- OPS201: Therapeutic-grade peptide enabling tumor cell-selective internal peptide receptor radionuclide therapy (PRRT) with 90Yttrium or 177Lutetium isotopes, targeting neuroendocrine tumors
- OPS202: Diagnostic-grade 68Gallium-labeled compound for PET imaging that detects neuroendocrine tumors by targeting somatostatin receptors, enabling identification of receptor-positive disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OctreoPharm Sciences
Estrella Biopharma
HQ: United States
Website
- Description: Provider of proprietary CD19-Redirected ARTEMIS T-cell therapies for cancer, designed to treat CD19-positive blood cancers with reduced risk of CRS and neurotoxicity. Offerings include a Mark-and-Kill approach using an oncolytic virus to label solid tumors for targeting by ARTEMIS T Cells, EB104 (CD19/CD22) for blood cancers, and EB103 combined with an oncolytic virus for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Estrella Biopharma company profile →
OnKure Therapeutics
HQ: United States
Website
- Description: Provider of next-generation oncology precision medicines targeting validated cancer drivers, developed by a clinical-stage biopharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OnKure Therapeutics company profile →
Molecular Insight
HQ: United States
Website
- Description: Provider of biopharmaceutical innovations in molecular medicine, applying molecular-level disease identification and targeting to improve patient healthcare and address significant unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Insight company profile →
Cabrellis
HQ: United States
Website
- Description: Provider of specialty pharmaceutical cancer therapy development, planning three small cell lung cancer clinical trials in 2006, including a study assessing the safety and efficacy of Calsed(TM) in reference to topotecan for second-line treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cabrellis company profile →
NeoGenomics
HQ: United States
Website
- Description: Provider of cancer testing and partnership programs for pathologists and oncologists, offering diagnostic services (flow cytometry, FISH, cytogenetics, and next-generation sequencing for solid tumors and hematologic cancers), anatomic pathology (histology, tissue staining, digital pathology), NGS panels including Neo Comprehensive™ – Heme Cancers, Early-stage NSCLC Panel, InVisionFirst®-Lung, and pharma services for biomarker discovery, clinical trials, and companion diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoGenomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OctreoPharm Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OctreoPharm Sciences
2.2 - Growth funds investing in similar companies to OctreoPharm Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OctreoPharm Sciences
4.2 - Public trading comparable groups for OctreoPharm Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →